No donafenib or PD-1 inhibitor interruptions were observed, and 24 patients in the TACE+DP group who received camrelizumab developed RCCEP, a common skin toxicity caused by camrelizumab. The gene discussed is PDCD1; the disease is dermatological toxicity.